IHCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

Mühlberger, Nikolai; Schwarzer, Ruth; Lettmeier, Beate; Sroczynski, Gaby; Zeuzem, Stefan; Siebert, Uwe
January 2009
BMC Public Health;2009, Vol. 9 Issue 1, p1
Academic Journal
Background: Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed. Methods: Literature and international health databases were systematically searched for HCV-specific burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and liver transplantation. Data were collected for the WHO European region with emphasis on 22 countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions. Results: HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national surveillance are not fully comparable and need to be standardised. HCV prevalence data are often inconclusive. According to available data, an estimated 7.3-8.8 million people (1.1-1.3%) are infected in our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable. Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2 million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by patients in preventable disease stages. About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV. Conclusion: Our results indicate that hepatitis C is a major health problem and highlight the importance of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce, outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries. What is needed are public awareness, co-ordinated action plans, and better data. European physicians should be aware that many infections are still undetected, provide timely testing and antiviral treatment, and avoid iatrogenic transmission.


Related Articles

  • Metal Contents in the Liver of Patients with Chronic Liver Disease Caused by Hepatitis C Virus. Ebara, Masaaki; Fukuda, Hiroyuki; Hatano, Ryoji; Yoshikawa, Masaharu; Sugiura, Nobuyuki; Saisho, Hiromitsu; Kondo, Fukuo; Yukawa, Masae // Oncology;2003, Vol. 65 Issue 4, p323 

    Background/Aims: The aim of this study was to investigate the relationship between trace metals and the prevalence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or hepatic cirrhosis caused by hepatitis C virus (HCV). Methods: We measured the contents of copper, iron, and...

  • Hepatitis C Virus Network Based Classification of Hepatocellular Cirrhosis and Carcinoma. Tao Huang; Junjie Wang; Yu-Dong Cai; Hanry Yu; Kuo-Chen Chou // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Hepatitis C virus (HCV) is a main risk factor for liver cirrhosis and hepatocellular carcinoma, particularly to those patients with chronic liver disease or injury. The similar etiology leads to a high correlation of the patients suffering from the disease of liver cirrhosis with those suffering...

  • Hepatitis C: Symptoms.  // Hepatitis C (National Institute of Allergy/Infectious Disease);2009, p5 

    The article offers information on the symptoms of hepatitis C. It mentions that the patients suffering from hepatitis C have abdominal pain, loss of appetite and nausea or vomiting and symptoms of acute hepatitis C appear 6 to 12 weeks after exposure to the virus. It further mentions that in...

  • A patient with hepatitis C-related liver cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy. Shibata, Minoru; Yanaga, Katsuhiko; Morizane, Toshio; Yanagawa, Tatsuro; Hirakawa, Masami; Ueno, Yukihisa; Esquivel, Carlos O.; Mitamura, Keiji // Journal of Gastroenterology;2003, Vol. 38 Issue 6, p598 

    A patient with hepatitis C virus (HCV)-related liver cirrhosis and hepatocellular carcinoma (HCC) was treated successfully with an orthotopic liver transplantation (OLT) followed by interferon therapy. The 36-year-old Japanese man was diagnosed as having liver cirrhosis in 1983. HCC was detected...

  • Prevalence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis and Prior Exposure to Hepatitis C. Vamauchi, Masayoshi; Nakahara, Masao; Maezawa, Yoshihiko; Satoh, Shyunnya; Nishikawa, Fuminori; Ohata, Mituru; Mizuhara, Yuji; Hirakawa, Junnichi; Nakajima, Hisato; Fujisawa, Kiyoshi; Toda, Gotaro // American Journal of Gastroenterology;Jan1993, Vol. 88 Issue 1, p39 

    Sixty-three patients with alcoholic cirrhosis were retrospectively studied for the prevalence of antibodies to core (P22) and nonstructural (C100) region of hepatitis C virus (HCV). The prevalence rate of anti-F22 anti-bodies in patients with alcoholic cirrhosis was higher than that of anti-C100...

  • Global control of hepatitis C: where challenge meets opportunity. Thomas, David L // Nature Medicine;Jul2013, Vol. 19 Issue 7, p850 

    We are entering an important new chapter in the story of hepatitis C virus (HCV) infection. There are clear challenges and opportunities. On the one hand, new HCV infections are still occurring, and an estimated 185 million people are or have previously been infected worldwide. Most HCV-infected...

  • Arachidonic acid deficiency in mononuclear cells and its clinical significance in HCV cirrhotic patients. Sasagawa, Takayo; Tomioka, Kayoko; Ota, Yasuko; Kawata, Sunao; Nakayama, Toshiko; Osawa, Toshiya; Sakai, Nobuyuki; Kawaguchi, Mitsuhiko; Itoshima, Tatsuya; Okita, Misako // Asia Pacific Journal of Clinical Nutrition;2002 Supplement, Vol. 11, pS62 

    Aim: An abnormal fatty acid pattern in advanced liver cirrhotic (LC) patients has been reported in plasma phospholipids and some other tissues. We elucidated the significance of arachidonic acid deficiency on clinical pathophysiology of LC and hepatocellular carcinoma (HCC). Methods: We analyzed...

  • Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. Nahon, Pierre; Sutton, Angela; Rufat, Pierre; Simon, Chantal; Trinchet, Jean-Claude; Gattegno, Liliane; Beaugrand, Michel; Charnaux, Nathalie; Rodrigo, Luis; Shimada, Mitsuo; Einarsson, Curt // World Journal of Gastroenterology;2/7/2008, Vol. 14 Issue 5, p713 

    AIM: To explore the influence of polymorphisms in genes encoding for the chemokines Stromal cell-Derived Factor-1 (SDF-1)/CXCL12 and Monocyte Chemotactic Protein-1 (MCP-1) /CCL2, or for the chemokine receptor CCR5 on the risks of liver-related death and hepatocellular carcinoma (HCC) occurrence...

  • The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Goodgame, Boone; Shaheen, Nicholas J.; Galanko, Joseph; El-Serag, Hashem B. // American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2535 

    : ObjectivesIn persons infected with hepatitis C virus (HCV), the incidence of cirrhosis and hepatocellular carcinoma (HCC) can be estimated by examining over time entire cohorts with known onset of HCV infection. We performed a systematic review of the literature to identify and to analyze...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics